Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Remdesivir  COVID-19 treatment studies for Remdesivir  C19 studies: Remdesivir  Remdesivir   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ All patients 49% Improvement Relative Risk SpO2<95% 58% Clinical improvement 56% c19early.org/s Flisiak et al. Remdesivir for COVID-19 LATE TREATMENT Is late treatment with remdesivir beneficial for COVID-19? Retrospective 333 patients in Poland Greater improvement with remdesivir (p=0.01) Flisiak et al., medRxiv, doi:10.1101/2020.10.30.20215301 Favors remdesivir Favors control
Remdesivir-based therapy improved recovery of patients with COVID-19 in the SARSTer multicentre, real-world study
Flisiak et al., medRxiv, doi:10.1101/2020.10.30.20215301 (Preprint)
Flisiak et al., Remdesivir-based therapy improved recovery of patients with COVID-19 in the SARSTer multicentre, real-world.., medRxiv, doi:10.1101/2020.10.30.20215301 (Preprint)
Nov 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective study comparing 122 remdesivir patients and 211 lopinavir/ritonavir patients, showing higher rates of clinical improvement with remdesivir and lower mortality (not statistically significant).
[Gérard, Wu, Zhou] show significantly increased risk of acute kidney injury with remdesivir.
all patients, 48.9% lower, RR 0.51, p = 0.18, treatment 5 of 122 (4.1%), control 17 of 211 (8.1%), NNT 25, odds ratio converted to relative risk.
SpO2<95%, 58.0% lower, RR 0.42, p = 0.13, treatment 4 of 82 (4.9%), control 14 of 119 (11.8%), NNT 15, odds ratio converted to relative risk.
no clinical improvement, 56.5% lower, RR 0.44, p = 0.01, treatment 9 of 122 (7.4%), control 36 of 211 (17.1%), NNT 10, odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Flisiak et al., 3 Nov 2020, retrospective, Poland, preprint, 23 authors.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperRemdesivirAll
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2020.10.30.20215301; this version posted November 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Remdesivir-based therapy improved recovery of patients with COVID-19 in the SARSTer multicentre, real-world study Robert Flisiak1*#, Dorota Zarębska-Michaluk2*, Aleksandra Berkan-Kawińska3, Magdalena Tudrujek-Zdunek4, Magdalena Rogalska1, Anna Piekarska3, Dorota Kozielewicz5, Krzysztof Kłos6, Marta Rorat7,8, Beata Bolewska9, Anna Szymanek-Pasternak10, Włodzimierz Mazur11, Beata Lorenc12, Regina Podlasin13, Katarzyna Sikorska14, Barbara OczkoGrzesik15, Cezary Iwaszkiewicz16, Bartosz Szetela17, Paweł Pabjan2, Małgorzata Pawłowska5, Krzysztof Tomasiewicz4, Joanna Polańska18, Jerzy Jaroszewicz15. *equal contribution # Corresponding author: Prof. Robert Flisiak, Department of Infectious Diseases and Hepatology, Medical University of Bialystok, ul. Zurawia 14, 15-540, Bialystok, Poland. Tel./fax: +48 857416921. Email: robert.flisiak1@gmail.com 1 Department of Infectious Diseases and Hepatology, Medical University of Białystok, Białystok, Poland 2 Department of Infectious Diseases, Jan Kochanowski University, Kielce, Poland 3 Department of Infectious Diseases and Hepatology, Medical University of Łódź, Łódź, Poland 4 Department of Infectious Diseases and Hepatology, Medical University of Lublin, Lublin, Poland 5 Department of Infectious Diseases and Hepatology, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Poland 6 Department of Infectious Diseases and Allergology, Military Institute of Medicine, Warsaw, Poland 7 Department of Forensic Medicine, Wrocław Medical University, Wrocław, Poland 8 First Infectious Diseases Ward, Gromkowski Regional Specialist Hospital in Wrocław, Wrocław, Poland. 9 Department of Infectious Diseases, University of Medical Sciences, Poznań, Poland 10 Department of Infectious Diseases and Hepatology, Wrocław Medical University, Wrocław, Poland 11 Clinical Department of Infectious Diseases in Chorzów, Medical University of Silesia, Katowice, Poland 12 Pomeranian Center of Infectious Diseases, Department of Infectious Diseases, Medical University of Gdańsk, Gdańsk, Poland 13 Hospital of Infectious Diseases in Warsaw, Warsaw, Poland 14 Department of Tropical Medicine and Epidemiology, Medical University of Gdańsk, NOTE: ThisPoland preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. Gdańsk medRxiv preprint doi: https://doi.org/10.1101/2020.10.30.20215301; this version posted November 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . 15 Department of Infectious Diseases in Bytom, Medical University of Silesia, Katowice, Poland 16 Department of Rheumatology and Osteoporosis, Jozef Strus Hospital in Poznań, Poland 17 Department of Infectious Diseases, Liver Diseases and Acquired Immune Deficiencies, Wrocław Medical University, Wrocław, Poland 18 Department of Data Science and Engineering, Silesian University of Technology, Gliwice, Poland medRxiv preprint doi:..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit